Fresh analysis reveals that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle programs.
Findings released in a prominent health publication demonstrates that while obese people can lose substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these medications should be informed of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass in about a year and a half.
Weighing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the results of these new drugs with older methods.
Researchers point out that individuals who lose weight through diet and exercise usually have a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Regain
Doctors believe the mode of action of the drugs is key to understanding the heightened rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than normal might result in the system to produce less of its own natural hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating much more probable."
A Chronic Condition?
Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the high risk of weight regain, the therapy should be considered life-long.
This opinion is supported by pharmaceutical companies, who note that the results "underscore the persistent character of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Users who have come off the medication report a powerful return of appetite.
"I experienced something that goes on and you're instantly ravenous," said a patient.
This difficulty is exacerbated if individuals have not adopted permanent lifestyle or habit changes during therapy.
Widespread Interest
Figures show that millions of people in the UK have used these injections in the past year, with demand continuing to grow.
- Use is more common among women than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on ongoing lifestyle management.
